Prescribers of rosiglitazone (marketed by Avandia) were reminded by the Ministry of Health
to not disregard the restrictions for use of the drug in patients with cardiovascular disease.
Patients were advised to not stop taking rosiglitazone. Concerns over increased risk of myocardial infarction and cardiovascular death in patients with Type Two diabetes treated with Avandia is more imminent more so now than ever before.
The Drug Control Authority (DCA) continues to monitor the safety of rosiglitazone so that people will not have to worry about the safety of their medication. The labeling of Avandia will also be watched closely and the warning section will be strengthened so that heart failure occurs much less often or not at all.
The U.S. Food and Drug Administration (USFDA) have recently issued letters to the manufacturers of Avandia, warning them about their product.
For more information on this subject, please refer to our section on Drugs, Medical Devices, and Implants.